ESMO EnLiST框架:实体瘤系统治疗线数标准化共识
ESMO基于既往肿瘤治疗线数(LoT)提案,采用Delphi法纳入肿瘤内科医生、试验研究者、监管方、患者代表等多利益相关方共识,制定适用于实体瘤的EnLiST框架。该框架提供标准定义、LoT报告格式、最低数据记录要求及LoT分配指南,将LoT分别赋予早期(eLoT)、晚期(aLoT)和研究性(iLoT)场景,以小数点分隔的两个数字表示(如1.0),治疗变更分为新LoT、修改LoT或相同LoT。
要点
- EnLiST将LoT分别赋予早期、晚期和研究性系统抗癌治疗场景。
- LoT以小数点分隔的两个数字表示(如1.0),新LoT记小数点左侧递增(如2.0),修改LoT记小数点右侧递增(如1.1)。
- 新LoT源于疾病临床进展或肿瘤应答不足,修改LoT源于其他原因(如不可耐受)。
核心结论
- EnLiST为实体瘤系统治疗线数的定义、记录与报告提供标准化共识框架。
研究设计与样本
- ESMO采用Delphi流程,在肿瘤内科医生、临床试验研究者、监管方、学术界、患者倡导者、制药行业与临床研究组织专家、人工智能专业人员、资助机构专家及伦理学家等多利益相关方代表间达成共识。
主要发现
- EnLiST提供一套标准定义、LoT报告格式、最低数据记录要求及LoT分配指南。
- LoT分别赋予早期(eLoT)、晚期(aLoT)和研究性(iLoT)系统抗癌治疗场景,每个LoT以小数点分隔的两个数字表示(如1.0)。
- 系统抗癌治疗变更导致「新」LoT、「修改」LoT或「相同」LoT。
- 新LoT源于疾病临床进展或肿瘤应答不足,记录为小数点左侧下一个顺序值(如LoT 1.0之后的新LoT为LoT 2.0)。
- 因其他原因(如不可耐受)变更治疗时记录为修改LoT,赋予小数点右侧下一个顺序值(如LoT 1.0之后的修改LoT为LoT 1.1)。
关键数值与推荐
- LoT以两个数字表示,小数点分隔(如1.0),新LoT递增小数点左侧数值,修改LoT递增小数点右侧数值。
临床怎么用
- EnLiST旨在服务广泛利益相关方需求,同时提升临床诊疗、临床研究和真实世界数据的质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Enumeration of lines of therapy (LoT) is critical across oncology for ensuring optimal patient care, establishing uniform eligibility for clinical trial enrolment, standardising use of real-world data and pooling data for research purposes. Building on an earlier proposal for assigning LoT in oncology, the European Society for Medical Oncology (ESMO) developed the ESMO adaptation of Lines of Systemic Therapy (EnLiST) framework applicable to solid tumours across the full range of common clinical settings. A Delphi process was adopted to reach a consensus between expert representatives of multiple stakeholder perspectives including medical oncologists, clinical trialists, regulators, academics, patient advocates, experts from the pharmaceutical industry and clinical research organisations, artificial intelligence professionals, funding body specialists and ethicists. EnLiST provides a set of standard definitions, the format of reporting LoT, the minimum required data to be recorded and guidelines for assigning LoT. In EnLiST, a LoT is separately assigned to systemic anticancer therapies in the early (eLoT), advanced (aLoT) and investigational (iLoT) settings; each expressed as two numerals separated by a decimal point (e.g. 1.0). A change in systemic anticancer therapy results in either a 'New' LoT, a 'Modified' LoT, or the 'Same' LoT. A New LoT results from clinical progression of disease or lack of adequate tumour response, and is recorded as the next sequential value to the left of the decimal point (e.g. following LoT 1.0, the New LoT will be LoT 2.0). If the change in treatment is for other reasons (e.g. intolerability), a Modified LoT is recorded and assigned the next sequential value to the right of the decimal point (e.g. following LoT 1.0, the Modified LoT will be LoT 1.1). EnLiST has been designed to serve the needs of a wide range of stakeholders while enhancing the quality of clinical care, clinical research and real-world data.
引用
- Saini KS, Koopman M, Martins-Branco D, et al. ESMO adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours. Ann Oncol. 2026. PMID: 41713786. doi:10.1016/j.annonc.2026.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。